AMY HOFFMAN: Open Payments
NPI 1487888053 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 32 payments from 9 companies in 2025. Trend: 2023 $427 · 2024 $327 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $287 |
| Lilly USA, LLC | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Incyte Corporation | 2 | $43 |
| ABBVIE INC. | 2 | $38 |
| Amgen Inc. | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| GENZYME CORPORATION | 1 | $24 |
| Biofrontera Inc. | 1 | $19 |
Products named: TREMFYA, DUPIXENT, AXERT, OPZELURA, SKYRIZI, TALTZ, OTEZLA, COSENTYX.
Industry payments across MD — which companies pay providers there.
